🫀 Smart Drugs, Vulnerable Hearts: Antibody Drug Conjugates Cardiotoxicity in Breast Cancer

🎯 Target the Tumor, Guard the Heart! ❤️ Antibody-drug conjugates are transforming breast cancer therapy—but precision oncology does not eliminate cardiovascular risk. 🧬🫀 This excellent JACC: CardioOncology Primer explores how the antibody, linker & payload may contribute to cardiotoxicity. HER2-directed ADCs carry the clearest cardiac signal, with T-DXd showing higher and more variable LVEF decline than T-DM1, while TROP-2–directed ADCs currently show limited cardiac signals. 🔑 The future: risk-based surveillance, biomarkers, AI prediction & smarter ADC engineering. #CardioOncology #BreastCancer #ADCs #Cardiotoxicity #MedicalPodcasts